(NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products last year, as we headed toward a post-pandemic world, meant a big decline from those revenue levels, and that's weighed on share performance. Pfizer shares have tumbled 37% over the past year.

At the same time, some of Pfizer's other blockbusters are set to lose exclusivity later this decade, further weighing on earnings. So, you may not imagine Pfizer as a stock that could help you retire a millionaire. But it may be worth taking a second look at this big pharma player, because, despite these challenges, a new era of growth might be just ahead. Let's find out more.

Image source: Getty Images.

Continue reading

Source Fool.com